Home

What is the NILO-PD Study?

The Parkinson Study Group (PSG), under the direction of Tanya Simuni, MD (Northwestern University) is conducting a multi-center, randomized, double-blind, placebo-controlled study of nilotinib in individuals with Parkinson’s disease (PD).

The purpose of the NILO-PD study is to determine if nilotinib is safe, if it can be tolerated by patients with PD and to learn if nilotinib has the possibility of effectively treating PD symptoms. Twenty-five sites will enroll participants into 2 cohorts, approximately 75 in Cohort 1 and 60 in Cohort 2. Cohort 1 will be enrolling first and participants will have moderate to advanced PD. Cohort 2 will enroll after the completion of Cohort 1 and participants will have early PD.

NILO-PD is being conducted under a research grant award from the Michael J. Fox Foundation for Parkinson’s Research.